Back to results
US 2026/0306481 A1Published application
Rapid induction with monthly injectable buprenorphine extended-release
AssigneeIndivior UK Limited
InventorsChristian A. HEIDBREDER, Frank GRAY, Celine M. LAFFONT, Robert L. DOBBINS
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of treating opioid use disorder in a human by rapid induction with monthly injectable extended release buprenorphine, and to rapid induction dosage regimens for treating opioid use disorder. The methods provide increased treatment retention compared to standard of care methods.
Claims2
A method of treating opioid use disorder in a human in need thereof, the method comprising:
- (a) administering a composition comprising about 4 mg of transmucosal buprenorphine hydrochloride to the human on day 1,
- (b) administering about 300 mg of BUP-XR by subcutaneous injection to the human at least 1 hour later.
A method of treating opioid use disorder in a human in need thereof, the method comprising:
- (a) administering a composition comprising about 4 mg of transmucosal buprenorphine hydrochloride to the human on day 1,
- (b) administering about 300 mg of BUP-XR by subcutaneous injection 1 at least 1 hour later,
- (c) administering a second dose of 300 mg of BUP-XR to said human by subcutaneous injection 2 as early as day 8 or up to one month after injection 1,
- (d) administering 100 mg or 300 mg of BUP-XR monthly to the human by subcutaneous injection 3 starting one month from administration of said injection 2 and continuing monthly as long as needed,
- wherein, at least one of the following results is obtained:
- (i) completion of steps (a) through (b) has a retention rate superior to the standard of care induction at an endpoint of injection 2;
- (ii) completion of steps (a) though (b) does not increase Precipitated Opioid Withdrawal (POW) relative to the standard of care induction;
- (iii) for patients experiencing POW, retention at injection 1 is higher after completion of step (a) with RI than for standard of care induction;
- retention at injection 2 is higher after completion of steps (a) through (b) than for the standard of care induction;
- and retention at injection 3 is higher after completion of steps (a) through (c) than for standard of care induction;
- (iv) the Clinical Opiate Withdrawal Score (COWS) from completion of steps (a) through (b) during RI is lower than for the standard of care induction;
- (v) treatment-emergent adverse events (TEAEs) up to the second injection in the steps (a) through (b) are comparable to the TEAEs up to the second injection for the standard of care induction;
- or
- (vi) treatment-emergent adverse events (TEAEs) up to the third injection in the steps (a) through (c) were comparable to the TEAEs up to the third injection for the standard of care induction.
11 more elements
Dependencies are inferred from the claim text.